^
Association details:
| Biomarker: | CD19 positive |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug Class: | CAR-T immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy
Published date:
11/01/2018
Excerpt:
Twenty-one subjects with CD19+ rrALL received SCRI-CAR19v2...With a minimum of 1-year follow up (range 12-18 months), the 12-month event-free survival (EFS) and overall survival were 76% (95% CI 59-97) and 86% (95% CI 72-100), respectively... Of the 5 leukemic relapses, 1 lacked CD19 and 2 recurred as AML.
DOI:
https://doi.org/10.1182/blood-2018-99-110164
